NetworkNewsBreaks – PDS Biotechnology Corp. (NASDAQ: PDSB) Featured in Noble Capital Markets Research Update
PDS Biotechnology Corp. (NASDAQ: PDSB) was featured in a recent equity research update published by Noble Capital Markets. The report reads, “PDS Biotechnology is developing a platform technology known as Versamune for the treatment of cancer. Versamune consists of cationic (positively charged) lipids mix with tumor or viral antigens. Cationic lipids act as a vehicle to deliver the antigens to dendritic cells, which mature and help inducing a potent T-cell driven anti-cancer immune response.” To view the update and gain access to the full report, visit http://nnw.fm/j8Byw About PDS Biotechnology Corp. PDS Biotech is a clinical-stage immuno-oncology company developing multiple therapies…







